International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007

International Journal of Cancer

Volumn 139, Issue 7, 2016, Pages 1534-1545

  Petrick, Jessica L ^a   Braunlin, Megan ^a   Laversanne, Mathieu ^b   Valery, Patricia C ^c   Bray, Freddie ^b   McGlynn, Katherine A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

incidence; international; liver cancer; trends

Indexed keywords

ADULT; AFRICA; AGED; ARTICLE; ASIA; BILE DUCT CARCINOMA; CANCER INCIDENCE; EUROPE; FEMALE; FRANCE; HEPATITIS B VIRUS; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INDIA; ITALY; LIVER CANCER; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PACIFIC ISLANDS; PRIORITY JOURNAL; SEROPREVALENCE; SEX DIFFERENCE; THAILAND; TREND STUDY; WESTERN HEMISPHERE;

EID: 85027956702     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30211     Document Type: Article

References (35)

1. Ortman J, Velkoff V, Hogan H, An Aging Nation: The Older Population in the United States. U.S. Census Bureau, 2014.
2. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002;17:1049–55.
3. London WT, McGlynn KA. Liver Cancer. In: Schottenfeld D, Fraumeni JF. Cancer epidemiology and prevention, 3rd ed. Oxford; New York: Oxford University Press, 2006. 763–86.
4. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223–43. vii-x.
5. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015;19:223–38.
6. Zhang Y, Ren JS, Shi JF, et al. International trends in primary liver cancer incidence from 1973 to 2007. BMC Cancer 2015; 15:94
7. McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94:290–6.
8. Znaor A, Lortet-Tieulent J, Laversanne M, et al. International testicular cancer incidence trends: generational transitions in 38 countries 1900-1990. Cancer Causes Control 2015;26:151–8.
9. Trabert B, Chen J, Devesa SS, et al. International patterns and trends in testicular cancer incidence, overall and by histologic subtype, 1973-2007. Andrology 2015;3:4–12.
10. Segi M, Fujisaku S, Kurihara M. Geographical observation on cancer mortality by selected sites on basis of standardised death rate. Gann 1957;48:219–25.
11. Doll R, Payne P, Waterhouse J. Cancer Incidence in Five Continents: A Technical Reported. Berlin: Springer-Verlag, 1966.
12. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000; 19:335–51.
13. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995; 141:300–4.
14. Ferlay J, Rous B. Histological groups, Chapter 4. In: Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, SteliarovaFoucher E, Swaminathan R, Ferlay J, eds. Cancer Incidence in Five Continents, Vol X IARC Scientific Publication No 164 ed. Lyon: International Agency for Research on Cancer, 2014.
15. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469–81.
16. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987;6:449–67.
17. Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. Front Genet 2012;3:268
18. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. (Accessed on August 25, 2015).
19. Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013;34:1800–5.
20. Chen JG, Egner PA, Ng D, et al. Reduced aflatoxin exposure presages decline in liver cancer mortality in an endemic region of China. Cancer Prev Res (Phila) 2013;6:1038–45.
21. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878–87.
22. Gao S, Yang WS, Bray F, et al. Declining rates of hepatocellular carcinoma in urban Shanghai: incidence trends in 1976-2005. Eur J Epidemiol 2012;27:39–46.
23. Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008;148:820–6.
24. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–73 e1.
25. Centers for Disease Control and Prevention Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. MMWR 2012;61:6
26. Arnold M, Razum O, Coebergh JW. Cancer risk diversity in non-western migrants to Europe: an overview of the literature. Eur J Cancer 2010;46:2647–59.
27. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:1314–21.
28. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336–52.
29. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14.
30. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652–9.
31. Bruix J, Sherman M, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
32. Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut 2003;52:592–6.
33. Drenth JP. HCV treatment–no more room for interferonologists. N Engl J Med 2013;368:1931–2.
34. Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295–307.
35. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212–9.